Integris Medtech Ltd. IPO Details
Integris Medtech was incorporated on April 25, 2008. The company is a diversified India-based global MedTech and laboratory solutions provider, specialising in medical devices, diagnostics, and lab solutions. It is India’s second-largest coronary stent maker (22% DES market share) and Southeast Asia’s largest scientific laboratory solutions company
| Bidding Dates |
|---|
| To Be Announced |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 21.7 M | - | - | ₹9,250.0 M | DRHP DOC |
Integris Medtech issue details
Integris Medtech has 21.7 M shares on offer
Integris Medtech IPO issue size is ₹ 9,250.0 M
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 10% | 15% | 75% |
Integris Medtech IMPORTANT IPO DATES
| Issue Open Date | - |
| Issue close Date | - |
| Allotment Date | - |
| Refund Date | - |
| Demat Account Credit Date | - |
| Listing Date | - |
| Listing on Exchange(s) | NSE and BSE |
Integris Medtech NUMBER OF SHARES ON OFFER
Integris Medtech FINANCIALS
| Period | Revenue from Operations (Rs in crore) | Net Profit (Rs in crore) | Cash Flow from Operations (Rs in crore) | Free Cash Flow (Rs in crore) | Margins |
| Q1FY26 | 485.3 | 267.6 | 51.9 | 27.3 | 16.2% |
| FY25 | 1,902.5 | 70.7 | 155.5 | 74.6 | 16.3% |
| FY24 | 1,553.4 | -4.9 | 97.3 | 44.4 | 12.3% |
| FY23 | 1,348.1 | -40.5 | 19.4 | -30.0 | 12.5% |
Integris Medtech INFORMATION ON IPO ISSUE
About Integris Medtech
Integris Medtech was incorporated on April 25, 2008. The company is a diversified India-based global MedTech and laboratory solutions provider, specialising in medical devices, diagnostics, and lab solutions. It is India’s second-largest coronary stent maker (22% DES market share) and Southeast Asia’s largest scientific laboratory solutions company
Object of the Issue
- Repayment/ prepayment, in full or in part, of certain outstanding borrowings, interest accrued, and prepayment penalties, as applicable, availed by their wholly-owned Subsidiaries, namely, Translumina Therapeutics (“Translumina Therapeutics”), Transhealth (“Transhealth”), and HaleMed Medical
- Repayment/ prepayment, in full or in part, of certain outstanding borrowings, interest accrued, and prepayment penalties, as applicable, availed by their step-down subsidiaries, namely, CPC Diagnostics, Chemopharm Sdn. Bhd., Chemoscience Pte Ltd., Lifeline Diagnostics Supplies Inc., Hausen Bernstein Co. Ltd, Medigene Sdn. Bhd., Research Instruments Sdn Bhd and Research Instruments Pte. Ltd.
- General corporate purposes
Integris Medtech - PROMOTERS
| Name |
|---|
| Evercure Holdings Pte. Ltd. |
| Medicore Holdings Pte. Ltd. |
Integris Medtech - MANAGEMENT & LEADERSHIP
| Name | Designation |
|---|---|
| Annaswamy Vaidheesh | Chairperson & Non-Executive Independent Director |
| Probir Das | Executive Director & Group Chief Executive Officer |
| Rajani Kesari | Non-Executive Independent Director |
| Ramesh Subrahmanian | Non-Executive Independent Director |
| Gurmit Singh Chugh | Non-Executive Director |
| Avnish Mehra | Non-Executive Nominee Director |
| Punita Sharma | Non-Executive Director |
| Arjun Oberoi | Non-Executive Nominee Director |
| Vishal Omprakash Goenka | Non-Executive Nominee Director |
Integris Medtech Book Running Lead Manager
ICICI Securities Limited
integris.ipo@icicisecurities.com
Axis Capital Limited
integris.ipo@axiscap.in
Citigroup Global Markets India Private Limited
integrismedtech.ipo@citi.com
IIFL Capital Services Limited
integris.ipo@iiflcap.com
Integris Medtech Registrar to the Offer
KFin Technologies Limited
integris.ipo@kfintech.com
Integris Medtech Strengths
Risk-mitigated & scalable business model
The company operates a diversified global MedTech platform spanning research, diagnostics, and healthcare delivery. It supplies equipment and consumables to over 9,500 labs across Asia and serves major diagnostic chains like Dr. Lal Path Labs, Neuberg Labs, and Metropolis Healthcare
Acquisition-led expansion
The company has built a strong record of acquisition-led growth, evolving into a diversified and scalable MedTech platform. Its strategic acquisitions aim to expand geography, diversify offerings, enhance capabilities, and drive efficiencies for long-term value creation
Comprehensive laboratory solutions
The company is Southeast Asia’s largest scientific lab solutions provider, offering end-to-end services from sourcing to after-sales support. It partners with over 200 global suppliers to deliver advanced products, backed by logistics, installation, training, and technical support
Integris Medtech Risks
Permits & approvals
The company must obtain and maintain various statutory and regulatory approvals to operate its business. Delays or failures in securing these could impact product sales and operations, as its MedTech and lab solutions activities are subject to complex regulations across India and global markets
Quality
The company faces risks from product recalls, safety alerts, or regulatory actions, which could cause operational disruption, financial loss, and reputational damage. Its medical devices are subject to strict post-market surveillance, and defects or non-compliance may lead to mandated recalls, safety warnings, or marketing restrictions, with potential pricing and reimbursement limitations
Temperature-sensitive inventory
The company faces financial risks from temperature-sensitive inventory and supply chain disruptions. Cold chain failures, weather events, power outages, or operational errors could compromise product integrity, leading to inventory losses and affecting financial performance
IPO FAQs
The promoters of the company are Evercure Holdings Pte. Ltd. and Medicore Holdings Pte. Ltd..
The category allocation of qualified institutional buyers is 75.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 10.0%.